SecBot SecBot
Insider Cluster (3 insiders) ·Filed Jun 9, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago
Insider cluster: 3 insiders, $0.9M total
Actionable Insight • Neutral

Insider sales are immaterial in dollar terms and likely reflect routine diversification and option exercise tax planning. No bearish signal from this cluster.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$94.00
T+0 close · Jun 9, 2026 · via day close
Latest settled
+7.05%
T+60 · $100.63
Vs SPY
+0.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $94.00entry
  2. T+1 · 5mo ago +5.89%α +4.19% · $99.54
  3. T+5 · 5mo ago +8.03%α +4.60% · $101.55
  4. T+20 · 4mo ago +35.85%α +32.23% · $127.70
  5. T+60 · 2mo ago +7.05%α +0.47% · $100.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Mirum insiders, including the CEO and CFO, sold a total of $854K in open-market sales over a one-week window. The CFO also exercised and sold shares from option exercises, while the COO exercised options without selling. The sales represent ~0.015% of the $5.7B market cap, well below the 0.1% threshold for materiality, and the cluster includes a mix of cashless exercises and open-market sales, suggesting routine portfolio management rather than a coordinated bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$854.0K
Insiders
3

Key Facts

  • CEO Christopher Peetz sold 2.6K shares for $246K on 2026-06-01
  • Director Saira Ramasastry sold 4.0K shares for $398K on 2026-06-01
  • CFO Eric Bjerklolt sold 2.3K shares for $210K on 2026-06-08, following option exercises
  • Total open-market sales: $854K, representing ~0.015% of market cap
  • COO Peter Radovich exercised 16,988 options on 2026-06-05 but did not sell any shares

Financial Impact

Total insider sales of $854K, or ~0.015% of $5.7B market cap, trivial relative to company size

insider ownershipdilution

Risk Factors

  • Insider sales, while small, could be misinterpreted by retail traders as a negative signal
  • The CEO and CFO both sold, which may raise questions if followed by larger sales

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1781054493725

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026